Barclays
CRBP icon

Barclays’s Corbus Pharmaceuticals CRBP Stock Holding History

Barclays’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$27K – 4923
2020
Q3 		$27K Buy
+500
New +$90.6K ﹤0.01% 4836
2020
Q2 		– Sell
-320
Closed -$50K – 5655
2020
Q1 		$50K Buy
+320
New +$54.1K ﹤0.01% 5229
2017
Q1 		– Sell
-4,007
Closed -$1.02M – 6779
2016
Q4 		$1.02M Buy
+4,007
New +$918K ﹤0.01% 2730

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's CRBP Position: Q1 2026 in Review

Barclays increased its Corbus Pharmaceuticals (CRBP) stake by 41% in Q1 2026, buying an estimated $50.7K and bringing the position to 20,782 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3699.

Barclays first reported a position in CRBP in Q4 2016 and has held it in 29 quarters since. The position peaked at $7.27M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Barclays held 20,782 shares of Corbus Pharmaceuticals worth $195K as of Q1 2026.
  • Barclays bought 6,024 Corbus Pharmaceuticals shares in Q1 2026, an estimated $50.7K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3699 holding.
  • Barclays first reported a position in Corbus Pharmaceuticals in Q4 2016 and has held it in 29 quarters since.
  • Barclays's Corbus Pharmaceuticals position peaked at $7.27M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.